The "reimportation" of some prescription drugs is now legal in Maine, and it is far from the simple issue it can be portrayed as, Roger Pilon writes. Without strong intellectual property protections, drugmakers could not undertake costly and time-consuming research to support new drug approvals, and the reimportation of treatments at artificially low costs from nations with price controls undermines pharmaceutical innovation.

Related Summaries